HIV DNA vaccine test for people on stable treatment
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study tests a new DNA vaccine (ICVAX) designed to help your immune system better control HIV. You'll receive injections over several months if your HIV is well-controlled with current medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- HIV-positive and have been on antiviral medication (ART) for at least 12 months with no resistance
- Your viral load (amount of HIV in blood) has been undetectable (<50 copies/ml) for at least 12 months
- Your CD4 count (immune cells) is above 350 cells/μL in the past 6 months and was above 200 before starting treatment
- Age 18–60 and have a healthy weight (BMI 18.5–24.9)
- Willing to use approved contraception during the study (2-year commitment for some participants)
- No active opportunistic infections, hepatitis B or C, or autoimmune diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination HIV vaccine in healthy adults to see if it is safe and produces an immune response. If you are at low risk for HIV, you may help researchers learn more about future prevention strategies.
This study tests a new HIV vaccine in healthy, HIV-negative adults to see if it is safe and creates an immune response. The vaccine uses DNA and a protein to try to teach your body to fight HIV.
This study tests a new vaccine designed to help your immune system fight HIV better. It is for people with HIV who are already on effective antiretroviral therapy and have a well-controlled virus. The goal is to see if the vaccine is safe and boosts your body's natural defenses.
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
This study tests an experimental HIV vaccine that uses tiny particles and mRNA technology in healthy adults. If you qualify, you'll help researchers see if it's safe and if it triggers an immune response.
This trial tests a combination of an HIV vaccine and a new antibody treatment (GS-2872) to see if it can help control HIV without daily pills. It is for people with well-controlled HIV who are looking for ways to reduce their dependence on antiretroviral therapy.
Hear when a new Human Immunodeficiency Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.